Advertisement
YOU ARE HERE: LAT HomeCollectionsUpsher Smith Laboratories Inc
IN THE NEWS

Upsher Smith Laboratories Inc

FEATURED ARTICLES
BUSINESS
July 3, 2002 | Associated Press
A judge dismissed Federal Trade Commission charges that Schering-Plough Corp. and Upsher-Smith Laboratories Inc. colluded to set prices for a blood pressure drug. The decision by an FTC administrative law judge is a defeat for the FTC's concerted push against what it sees as a pattern of anti-competitive practices within the drug industry that is keeping cheap generics off the market.
ARTICLES BY DATE
BUSINESS
July 4, 2002 | Reuters
The Federal Trade Commission said it will pursue its case against Schering-Plough Corp. and Upsher-Smith Laboratories for allegedly using a patent settlement to keep cheaper versions of a popular heart medication off the market. An FTC administrative law judge ruled earlier that the agency had failed to prove the 1997 patent settlement between the companies was aimed at thwarting competition.
Advertisement
BUSINESS
July 4, 2002 | Reuters
The Federal Trade Commission said it will pursue its case against Schering-Plough Corp. and Upsher-Smith Laboratories for allegedly using a patent settlement to keep cheaper versions of a popular heart medication off the market. An FTC administrative law judge ruled earlier that the agency had failed to prove the 1997 patent settlement between the companies was aimed at thwarting competition.
BUSINESS
July 3, 2002 | Associated Press
A judge dismissed Federal Trade Commission charges that Schering-Plough Corp. and Upsher-Smith Laboratories Inc. colluded to set prices for a blood pressure drug. The decision by an FTC administrative law judge is a defeat for the FTC's concerted push against what it sees as a pattern of anti-competitive practices within the drug industry that is keeping cheap generics off the market.
BUSINESS
March 10, 2005 | From Reuters
An appeals court sided with Schering-Plough Corp., rejecting a finding by U.S. antitrust enforcers that the company illegally kept less expensive versions of the high blood pressure drug K-Dur off the market. A three-judge panel of the U.S. 11th Circuit Court of Appeals in Atlanta on Tuesday rejected a 2003 Federal Trade Commission ruling that Schering-Plough's settlements of patent suits with Upsher-Smith Laboratories Inc.
Los Angeles Times Articles
|